These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23084856)

  • 21. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.
    Bleiber G; Munoz M; Ciuffi A; Meylan P; Telenti A
    J Virol; 2001 Apr; 75(7):3291-300. PubMed ID: 11238855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
    Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
    J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses.
    Wei X; Liang C; Götte M; Wainberg MA
    AIDS; 2002 Dec; 16(18):2391-8. PubMed ID: 12461412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The G490E mutation in reverse transcriptase does not impact tRNA primer selection by HIV-1 with altered PBS and A-loop.
    Xu W; Morrow CD
    Virology; 2006 Sep; 352(2):380-9. PubMed ID: 16781756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.
    Hu Z; Kuritzkes DR
    J Virol; 2011 Nov; 85(21):11309-14. PubMed ID: 21849432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.
    Turner D; Brenner BG; Routy JP; Petrella M; Wainberg MA
    New Microbiol; 2004 Apr; 27(2 Suppl 1):31-9. PubMed ID: 15646062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Determination of HIV-1 RT Mutation Rate, Its Possible Allosteric Effects, and Its Implications on Drug Resistance.
    Yeo JY; Goh GR; Su CT; Gan SK
    Viruses; 2020 Mar; 12(3):. PubMed ID: 32182845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations that confer resistance to template-analog inhibitors of human immunodeficiency virus (HIV) type 1 reverse transcriptase lead to severe defects in HIV replication.
    Fisher TS; Joshi P; Prasad VR
    J Virol; 2002 Apr; 76(8):4068-72. PubMed ID: 11907245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Replication of chimeric human immunodeficiency virus type 1 (HIV-1) containing HIV-2 integrase (IN): naturally selected mutations in IN augment DNA synthesis.
    Padow M; Lai L; Deivanayagam C; DeLucas LJ; Weiss RB; Dunn DM; Wu X; Kappes JC
    J Virol; 2003 Oct; 77(20):11050-9. PubMed ID: 14512553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates.
    Rezende LF; Prasad VR
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1716-34. PubMed ID: 15183340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus.
    de Ronde A; van Dooren M; van Der Hoek L; Bouwhuis D; de Rooij E; van Gemen B; de Boer R; Goudsmit J
    J Virol; 2001 Jan; 75(2):595-602. PubMed ID: 11134272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.
    Pingen M; Wensing AM; Fransen K; De Bel A; de Jong D; Hoepelman AI; Magiorkinis E; Paraskevis D; Lunar MM; Poljak M; Nijhuis M; Boucher CA;
    Retrovirology; 2014 Nov; 11():105. PubMed ID: 25575025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.
    Bouchonnet F; Dam E; Mammano F; de Soultrait V; Henneré G; Benech H; Clavel F; Hance AJ
    J Virol; 2005 Jan; 79(2):812-22. PubMed ID: 15613309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions.
    Deval J; Navarro JM; Selmi B; Courcambeck J; Boretto J; Halfon P; Garrido-Urbani S; Sire J; Canard B
    J Biol Chem; 2004 Jun; 279(24):25489-96. PubMed ID: 15044478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity.
    Diallo K; Marchand B; Wei X; Cellai L; Götte M; Wainberg MA
    J Virol; 2003 Aug; 77(16):8621-32. PubMed ID: 12885880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The fidelity of misinsertion and mispair extension throughout DNA synthesis exhibited by mutants of the reverse transcriptase of human immunodeficiency virus type 2 resistant to nucleoside analogs.
    Taube R; Avidan O; Hizi A
    Eur J Biochem; 1997 Nov; 250(1):106-14. PubMed ID: 9431997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.
    Andreatta KN; Goodman DD; Miller MD; White KL
    Antimicrob Agents Chemother; 2015; 59(6):3441-9. PubMed ID: 25824231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.